louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06602206: Shoulder and Neck Mobilization in Patients With Subacromial Impingement Syndrome
Official title: Effects of Shoulder and Neck Mobilization on Pain, Sensation and Functionality in Patients With Subacromial Impingement Syndrome
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Subacromial Impingement Syndrome
Lead sponsor: Kutahya Health Sciences University
Sponsor class: OTHER
First posted: 2024-09-19
Enrollment: 45
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Patients who come to Tavşanlı State Hospital's Physical Therapy and Rehabilitation Department and have been diagnosed with subacromial impingement syndrome by a physician will be included. Patients will be selected by randomization method among the patients determined by the physician to receive conservative treatment, shoulder mobilization in addition to conservative treatment, and neck mobilization treatment program in addition to these. Conventional treatments such as hot packs, TENS, ultrasound, and exercise will be given to all patients by the hospital staff. Pain intensity will be evaluated with VAS. Additionally, painful arch and pain-free joint range of motion evaluation will be made using a goniometer. The DASH questionnaire will be used to evaluate shoulder functionality. Sensory evaluation will be made with pressure pain threshold and two-point discrimination tests. Measurements will be made before the intervention and repeated after 3 weeks of intervention.


Eligibility criteria: Inclusion Criteria:

* Being over 18 years of age
* Diagnosed with Subacromial Impingement
* Not having received any treatment for shoulder problems in the last 6 months
* The pain has been continuing for 3 months
* Initial pain must be 4 or higher on the Visual Analog Scale (VAS)

Exclusion Criteria:

* History of surgery in the shoulder, cervical and thoracic region
* Having a shoulder problem such as a frozen shoulder or instability
* Full-thickness rotator cuff tear
* Having systemic musculoskeletal disease
* Having systemic rheumatic disease
* History of upper extremity fracture
* Diagnosed with scoliosis
* Have neurological problems

Primary outcomes:
measure: Pain intensity
timeFrame: through study completion, an average of 1 year
Secondary outcomes:
measure: The Arm, Shoulder and Hand Problems (DASH) Questionnaire
timeFrame: through study completion, an average of 1 year
measure: Painful arch assessment
timeFrame: through study completion, an average of 1 year
measure: Painless range of motion assessment
timeFrame: through study completion, an average of 1 year
measure: Pressure-pain Threshold Assessment
timeFrame: through study completion, an average of 1 year
measure: Evaluation of Tactile Sensory Acuity
timeFrame: through study completion, an average of 1 year
Other outcomes:
Locations:
city: Kutahya
country: Turkey
facility: Kutahya Health Sciences University
Study officials:
affiliation: Kutahya Health Sciences University
name: Meltem Işıntaş
role: STUDY_DIRECTOR
References:
Clinical trial NCT03367806: Caffeine Consumption and Mortality in Diabetes
Official title: Caffeine Consumption and Mortality in Diabetes: an Analysis of National Health and Nutrition Examination Survey (NHANES) 1999-2010
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Diabetes Mellitus
Lead sponsor: Universidade do Porto
Sponsor class: OTHER
First posted: 2017-12-11
Enrollment: 3052
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: NHANES is a nationally-representative, cross-sectional study of nutrition and health for individuals residing in the U.S.

Brief summary: Previous studies suggested an inverse relationship between coffee consumption and mortality in the general population. Furthermore, an inverse association between coffee consumption and serum biomarkers of inflammation and insulin resistance has been described. Prospective studies showed that coffee consumption might be associated with reduction in the incidence of type 2 diabetes. Although caffeine consumption appears to be associated with a decreased risk of developing type 2 diabetes, the relationship between caffeine consumption and mortality in patients with diabetes remains uncertain. The current analysis aimed to assess the effects of caffeine consumption and caffeine source on all-cause, cardiovascular and cancer mortality among patients with diabetes.


Eligibility criteria: Inclusion Criteria:

* NHANES participants from 1999 to 2010 above 18-year old, with diagnosis of diabetes

Exclusion Criteria:

* Implausible alimentary reports (defined as consumption of less than 500 kcal/day or more than 3500 kcal/day)
* Missing information on caffeine consumption
* Missing information on mortality

Primary outcomes:
measure: All-cause mortality
timeFrame: From baseline until death or censoring on 31 December 2011, whichever came first, assessed up to 12 years
Secondary outcomes:
measure: Cardiovascular mortality
timeFrame: From baseline until death or censoring on 31 December 2011, whichever came first, assessed up to 12 years
measure: Cancer mortality
timeFrame: From baseline until death or censoring on 31 December 2011, whichever came first, assessed up to 12 years
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00726206: Correlation Between the Analysis of the Rapid Cortical Oscillations, the General Movements of the Preterm's and the Cerebral Palsy
Official title: Correlation Between the Analysis of the Rapid Cortical Oscillations, the General Movements of the Preterm's and the Cerebral Palsy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cerebral Palsy
Lead sponsor: Assistance Publique Hopitaux De Marseille
Sponsor class: OTHER
First posted: 2008-07-31
Enrollment: 44
Sex: ALL
Maximum age (years): 23
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: The general movement and the electroencephalogram analysis of the preterm have a high predictive value of the neuro-developmental outcome of the infants.

Detailed description: Compare the technical and the predictive characteristics of the qualitative analysis of the spontaneous motility with those of actual exams of reference diagnosis : magnetic resonance imaging, electroencephalogram and transfontanellar imaging.

Eligibility criteria: Inclusion Criteria:

* Children been born between 15/01/08 and 15/01/10
* children whose term is lower than 28 weeks of amenorrhoea

Exclusion Criteria:

* Born child superior to 28 weeks of amenorrhoea
* presenting child a genic syndrome, an evolutionary neurological disease, a pathology malformative

Primary outcomes:
measure: To prove the predictive value of the " Deltas Brushes " triggered by hand or foot stimulation in correlation with the general movement analysis in the cerebral palsy diagnosis.
timeFrame: 36 months
Secondary outcomes:
measure: To prove that the general movement of the preterm increases the predictive value the actual monitoring of the preterm's in the diagnosis of cerebral palsy.
timeFrame: 36 months
Other outcomes:
Locations:
city: Marseille
country: France
facility: Service de Médecine Infantile et Néonatologie, CHU Nord
Study officials:
affiliation: Assistance Publique des Hopitaux de Marseille
name: Catherine GIRE, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04197206: Ultrasound Guided Costotransverse Block for Breast Cancer Surgery
Official title: Evaluation of Ultrasound Guided Costotransverse Block in Breast Canser Surgery Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Postoperative Pain
Keywords: ultrasound guided block
Lead sponsor: Cigli Regional Training Hospital
Sponsor class: OTHER
First posted: 2019-12-13
Enrollment: 70
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Costotransverse block is a novel regional anesthesia technique described a few months ago. It's use for breast surgery has been reported by only one case report in the literature. As the investigators have considered that Costotransverse block can be efficacious for providing postoperative analgesia in the breast surgeries, the investigators have implemented the application of this blockade into practice at the clinic. The main purpose of this study is to evaluate the analgesic effect of ultrasound-guided unilateral costotransverse block in breast cancer surgery.


Eligibility criteria: Inclusion Criteria:

* patients undergoing breast canser surgery under general anesthesia ASA I-II

Exclusion Criteria:

* patients undergoing breast surgery under paravertebral block and others morbidly obesity ASA III - IV infection of the skin at the site of needle puncture area patients with known allergies to any of the study drugs coagulopathy recent use of analgesic/steroid drugs

Primary outcomes:
measure: 24 hours morphine consumption
timeFrame: 24 hours
Secondary outcomes:
measure: Numeric rating scale for postoperative pain intensity
timeFrame: 24 hours
Other outcomes:
Locations:
city: İzmir
country: Turkey
facility: Cigli regional research hospital
Study officials:
References:
citation: Aygun H, Thomas DT, Nart A. Ultrasound guided single injection costotransverse block in a breast conserving surgery patient; The first clinical report for novel interfascial block. J Clin Anesth. 2020 May;61:109647. doi: 10.1016/j.jclinane.2019.109647. Epub 2019 Oct 26. No abstract available.
citation: Nielsen MV, Moriggl B, Hoermann R, Nielsen TD, Bendtsen TF, Borglum J. Are single-injection erector spinae plane block and multiple-injection costotransverse block equivalent to thoracic paravertebral block? Acta Anaesthesiol Scand. 2019 Oct;63(9):1231-1238. doi: 10.1111/aas.13424. Epub 2019 Jul 23.
citation: Aygun H, Kiziloglu I, Ozturk NK, Ocal H, Inal A, Kutlucan L, Gonullu E, Tulgar S. Use of ultrasound guided single shot costotransverse block (intertransverse process) in breast cancer surgery: a prospective, randomized, assessor blinded, controlled clinical trial. BMC Anesthesiol. 2022 Apr 18;22(1):110. doi: 10.1186/s12871-022-01651-3.
Clinical trial NCT01460706: Imaging Malignant Glioma With 68Ga-DOTATOC PET/CT
Official title: PET/CT Imaging of Malignant Glioma With Somatostatin Analog 68Ga-DOTATOC
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
PHASE3
Conditions: Glioma
Keywords: Glioma
68Ga-DOTATOC
PET/CT
Somatostatin receptor
Lead sponsor: Turku University Hospital
Sponsor class: OTHER_GOV
First posted: 2011-10-27
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: The purpose of this study is to characterize tumour uptake of somatostatin analog 68Ga-DOTATOC in patients with either primary or recurrent malignant glioma. The investigators hypothesis is that some primary and recurrent malignant gliomas overexpress SST2 receptor which can be imaged with 68Ga-DOTATOC PET/CT. The investigators also hypothesize that tumor uptake of 68Ga-DOTATOC correlates with immunohistochemically determined SST2 receptor status of the tumor specimen.


Eligibility criteria: Inclusion Criteria:

* Age: 18 to 70 years old
* Language spoken: Finnish or Swedish
* Performance status: Karnofsky score 70 or better or WHO performance status 2 or better
* Supratentorial malignant glioma based on MRI imaging
* Supratentorial recurrent glioma based on MRI and/or \[11C\]methionine PET imaging
* Patients must be able to understand the meaning of the study and sign the appropriate Ethical Committee approved informed consent documents in the presence of the designated staff

Exclusion Criteria:

* Any medical or psychiatric condition that compromises the subject´s ability to participate in the study
* Any other significant disease including liver or renal disease
* Pregnant or lactating women

Primary outcomes:
measure: Malignant glioma uptake of 68Ga-DOTATOC
timeFrame: within 90 minutes post-injection
Secondary outcomes:
measure: Immunohistochemical SST2 receptor status of the tumor specimen
timeFrame: After glioma surgery within 4 weeks of PET/CT imaging
Other outcomes:
Locations:
city: Turku
country: Finland
facility: Turku PET Centre, Turku University Hospital
Study officials:
affiliation: Turku University Hospital
name: Heikki RI Minn, M.D., Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Kiviniemi A, Gardberg M, Frantzen J, Pesola M, Vuorinen V, Parkkola R, Tolvanen T, Suilamo S, Johansson J, Luoto P, Kemppainen J, Roivainen A, Minn H. Somatostatin receptor subtype 2 in high-grade gliomas: PET/CT with (68)Ga-DOTA-peptides, correlation to prognostic markers, and implications for targeted radiotherapy. EJNMMI Res. 2015 Apr 22;5:25. doi: 10.1186/s13550-015-0106-2. eCollection 2015.
Clinical trial NCT02036606: Racing and Crowded Thoughts in Mood Disorders
Official title: Psychopathological and Cognitive Mechanisms of Racing and Crowded Thoughts in Mood Disorders
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Bipolar Disorder
Lead sponsor: University Hospital, Strasbourg, France
Sponsor class: OTHER
First posted: 2014-01-15
Enrollment: 220
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Primary care clinic

Brief summary: Racing thoughts relate to subjective acceleration of thinking which has been essentially associated with manic episodes in bipolar disorder. Qualitatively, the phenomenology of racing thoughts in major depression seems to differ from rumination and pure manic racing thoughts: thoughts of all kinds accumulate in the patient's head. Recent qualitative evidence is consistent with the existence of these two kinds of "thought overactivity" related to mood disorders. In order to evaluate this and better understand the psychopathological and cognitive mechanisms that underlie thought overactivity in mood disorders, we have created a 34-item self-questionnaire - the Racing and Crowded Thoughts Questionnaire (RCTQ) and a number of neuropsychological tasks (time perception, cognitive flexibility). Also, given the relationship between mood disorders and creativity, it is likely that thought overactivity is related to increased creativity. We aim at evaluating this relationship through the French version of the Cognitive Processes Associated with Creativity scale (CPAC).


Eligibility criteria: Inclusion Criteria:

* Bipolar disorder or depressive disorder
* 18 -65 years old

Exclusion Criteria:

* neurological conditions or sequelae
* substance abuse in the last 10 months
* schizophrenia
* ADHD
* Borderline personality disorder
* Pregnant women- Subjects under legal supervision

Primary outcomes:
measure: Validation of the scale of Crowded Racing Thoughts Questionary = (RCTQ scale that assesses the two forms of racing thoughts)
timeFrame: one week
Secondary outcomes:
measure: Evaluation of executive and temporal mechanisms involved in racing thoughts
timeFrame: one week
Other outcomes:
measure: Validation of the French version of the scale Cognitive Processes Associated with Creativity or CPAC scale (scale that assesses creativity)
timeFrame: one week
Locations:
city: Strasbourg
country: France
facility: Service de psychiatrie 2 , Les Hôpitaux Universitaires de Strasbourg
state: Alsace
Study officials:
affiliation: Les Hôpitaux Universitaires de Strasbourg
name: Gilles Bertschy, PHDMD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01628406: Patient Registry of the Neurosurgery Department
Official title: Patient Registry of the Neurosurgery Department.
Study type: OBSERVATIONAL
Overall status: ENROLLING_BY_INVITATION
Conditions: Patients Treated at the Neurosurgery Department
Lead sponsor: University of Zurich
Sponsor class: OTHER
First posted: 2012-06-26
Enrollment: 18000
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All patients treated at the Neurosurgery Department

Brief summary: The investigators record all indications, treatments and outcomes from patients treated at the Neurosurgery Department.

* Trial with surgical intervention


Eligibility criteria: Inclusion criteria:

All patients treated at the Neurosurgery Department

Exclusion criteria:

None

Primary outcomes:
measure: neurological outcome
timeFrame: 1 year
measure: social outcome
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Zurich
country: Switzerland
facility: University Hospital Zurich, Neurosurgery
state: ZH
Study officials:
affiliation: University Hospital Zurich, Division of Neurosurgery
name: Johannes Sarnthein, Prof Dr
role: PRINCIPAL_INVESTIGATOR
affiliation: University Hospital Zurich, Division of Neurosurgery
name: Luca Regli, Prof Dr
role: PRINCIPAL_INVESTIGATOR
References:
citation: Sarnthein J, Staartjes VE, Regli L; Neurosurgery-Registry consortium. Neurosurgery outcomes and complications in a monocentric 7-year patient registry. Brain Spine. 2022 Jan 19;2:100860. doi: 10.1016/j.bas.2022.100860. eCollection 2022.
Clinical trial NCT07020806: [68Ga]Ga DOTA-5G as a Diagnostic Imaging Agent for Metastatic/Advanced Invasive Lobular Breast Cancer (LBC)
Official title: [68Ga]Ga DOTA-5G as a Diagnostic Imaging Agent for Metastatic/Advanced Invasive Lobular Breast Cancer (LBC)
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE1
Conditions: Metastatic Lobular Breast Carcinoma
Lead sponsor: University of California, Davis
Sponsor class: OTHER
Collaborators: name: Dr. Helen K Chew, University of California Davis
name: Dr. Cameron Foster, University of California Davis
name: Society of Nuclear Medicine and Molecular Imaging
First posted: 2025-06-13
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 89
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: This is a prospective study using \[68Ga\]Ga DOTA-5G PET/CT imaging in patients diagnosed with metastatic/advanced invasive lobular breast cancer (LBC).

Detailed description: This is a phase I investigator-initiated study that will investigate \[68Ga\]Ga DOTA-5G in patients with metastatic/advanced invasive LBC. 30 patients diagnosed with LBC will be enrolled over a 24-month period.

We hypothesize that a) \[68Ga\]Ga DOTA-5G will detect lesions in patients with invasive LBC, b) \[68Ga\]Ga DOTA-5G will be safe and well tolerated, and that c) \[68Ga\]Ga DOTA-5G PET/CT is more sensitive than 18F-FDG PET/CT at detecting lesions.

Eligibility criteria: Inclusion Criteria:

* (Ability to understand and willingness to sign a written informed consent document.
* Men and women age ≥ 18 yrs
* Confirmed presence of metastatic/advanced invasive lobular breast cancer and measurable disease per RECIST (version 1.1)
* Available archival tumor tissue
* Eastern Cooperative Oncology Group Performance Status ≤ 2
* Hematologic parameters defined as: Absolute neutrophil count (ANC) ≥ 1000 cells/mm3,Platelet count ≥ 100,000/mm3, Hemoglobin ≥ 8 g/dL.
* Blood chemistry levels defined as: AST, ALT, alkaline phosphatase ≤ 5 times upper limit of normal (ULN), Total bilirubin ≤ 2 times ULN, creatinine clearance \>60 mL/min.
* Anticipated life expectancy ≥ 3 months
* Able to remain motionless for up to 30-60 minutes per scan.

Exclusion Criteria:

* Pregnant and lactating women
* Prisoners
* Concurrent malignancy of a different histology that could confound imaging interpretation.
* Patients who cannot undergo PET/CT scanning because of weight limits(\>350lbs)

Primary outcomes:
measure: The ability of [68Ga]Ga DOTA-5G PET/CT imaging to detect lesions
timeFrame: 2 hours from time of injection
measure: Safety and tolerability of [68Ga]Ga DOTA-5G based on the incidence of adverse events using CTCAE v 5.0
timeFrame: Up to 7 days from time of injection
Secondary outcomes:
Other outcomes:
Locations:
city: Sacramento
country: United States
facility: University of California Davis
state: California
Study officials:
affiliation: University of California, Davis
name: Julie Sutcliffe, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00761306: Open-label Safety Extension Study of 5 and 10 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults
Official title: A Long-term, Open-label Study Evaluating the Safety and Tolerability of [Vortioxetine] Lu AA21004 in Patients With Major Depressive Disorder
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Major Depressive Disorder
Keywords: Major Depressive Disorder
Long-term
Safety
Open-label
Lead sponsor: H. Lundbeck A/S
Sponsor class: INDUSTRY
First posted: 2008-09-29
Enrollment: 74
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of the study is to evaluate long-term safety and tolerability of Vortioxetine over a period of 52 weeks in patients with Major Depressive Disorder (MDD) having completed 6-week acute treatment in study NCT00839423 / 11492A.


Eligibility criteria: Inclusion Criteria:

- Patients who completed 6-week short-term treatment study for Major Depressive Episode (MDE), NCT00839423 / 11492A, followed by a 2-week taper period

Exclusion Criteria:

* Any current psychiatric disorder other than MDD as defined in the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSM-IV TR)
* Female patients of childbearing potential who are not using effective contraception
* Use of any psychoactive medication

Other protocol-defined inclusion and exclusion criteria may apply.

Primary outcomes:
measure: Number of Patients With Adverse Events (AEs)
timeFrame: Up to 52 weeks and a 4-week safety follow-up period
measure: Percentage of Patients Who Withdrew Due to Intolerance to Treatment
timeFrame: Baseline to Week 52
Secondary outcomes:
measure: Change From Baseline in MADRS Total Score After 52 Weeks of Treatment
timeFrame: Baseline and Week 52
measure: Change From Baseline in HAM-D-24 Total Score After 52 Weeks of Treatment
timeFrame: Baseline and Week 52
measure: Proportion of Responders at Week 52 (Response Defined as a >=50% Decrease in MADRS Total Score)
timeFrame: Week 52
measure: Proportion of Remitters at Week 52 (Remission Defined as a MADRS Total Score <=10)
timeFrame: Week 52
Other outcomes:
Locations:
Study officials:
affiliation: LundbeckClinicalTrials@lundbeck.com
name: Email contact via H. Lundbeck A/S
role: STUDY_DIRECTOR
References: